TY - JOUR
T1 - Pathways to Parkinson’s disease
T2 - a spotlight on 14-3-3 proteins
AU - Giusto, E.
AU - Yacoubian, T. A.
AU - Greggio, E.
AU - Civiero, L.
N1 - Funding Information:
University of Padova to support L.C. as assistant professor and the IRCCS San Camillo Hospital in Venice, Italy. This work was supported by UniPD (STARs 2019: Supporting TAlents in ReSearch), the Italian Ministry of Health (GR-2016-02363461) to L.C., and the IRCCS San Camillo Hospital in Venice, Italy. T.A.Y. was supported by the NIH/ NINDS grants R01NS112203, R56NS115767, and P50NS108675. We are also grateful to the Michael J Fox Foundation for supporting E.G.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/9/21
Y1 - 2021/9/21
N2 - 14-3-3s represent a family of highly conserved 30 kDa acidic proteins. 14-3-3s recognize and bind specific phospho-sequences on client partners and operate as molecular hubs to regulate their activity, localization, folding, degradation, and protein–protein interactions. 14-3-3s are also associated with the pathogenesis of several diseases, among which Parkinson’s disease (PD). 14-3-3s are found within Lewy bodies (LBs) in PD patients, and their neuroprotective effects have been demonstrated in several animal models of PD. Notably, 14-3-3s interact with some of the major proteins known to be involved in the pathogenesis of PD. Here we first provide a detailed overview of the molecular composition and structural features of 14-3-3s, laying significant emphasis on their peculiar target-binding mechanisms. We then briefly describe the implication of 14-3-3s in the central nervous system and focus on their interaction with LRRK2, α-Synuclein, and Parkin, three of the major players in PD onset and progression. We finally discuss how different types of small molecules may interfere with 14-3-3s interactome, thus representing a valid strategy in the future of drug discovery.
AB - 14-3-3s represent a family of highly conserved 30 kDa acidic proteins. 14-3-3s recognize and bind specific phospho-sequences on client partners and operate as molecular hubs to regulate their activity, localization, folding, degradation, and protein–protein interactions. 14-3-3s are also associated with the pathogenesis of several diseases, among which Parkinson’s disease (PD). 14-3-3s are found within Lewy bodies (LBs) in PD patients, and their neuroprotective effects have been demonstrated in several animal models of PD. Notably, 14-3-3s interact with some of the major proteins known to be involved in the pathogenesis of PD. Here we first provide a detailed overview of the molecular composition and structural features of 14-3-3s, laying significant emphasis on their peculiar target-binding mechanisms. We then briefly describe the implication of 14-3-3s in the central nervous system and focus on their interaction with LRRK2, α-Synuclein, and Parkin, three of the major players in PD onset and progression. We finally discuss how different types of small molecules may interfere with 14-3-3s interactome, thus representing a valid strategy in the future of drug discovery.
UR - http://www.scopus.com/inward/record.url?scp=85115360805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115360805&partnerID=8YFLogxK
U2 - 10.1038/s41531-021-00230-6
DO - 10.1038/s41531-021-00230-6
M3 - Review article
AN - SCOPUS:85115360805
SN - 2090-8083
VL - 7
JO - npj Parkinson's Disease
JF - npj Parkinson's Disease
IS - 1
M1 - 85
ER -